Vancomycin with piperacillin-tazobactam is used as empirical therapy for critically ill patients. Studies of this combination against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-intermediate S. aureus (VISA) are limited, but β-lactams in combination with vancomycin have shown synergistic activity against MRSA and VISA. The goal of this study was to evaluate whether piperac...

BACKGROUND The Clinical and Laboratory Standards Institute (CLSI) recently elected to adjust the previous piperacillin susceptibility breakpoint of ≤64 µg/mL against Pseudomonas aeruginosa to ≤16 µg/mL, based largely on pharmacokinetic-pharmacodynamic (PK-PD) modeling studies. Data on whether PK-PD modeling correlates with clinical outcomes in children are needed before resorting to broader cla...

Although excessive dose of piperacillin predominantly eliminated by the kidneys can cause encephalopathy in patients with impaired renal function, its standard dose causing acute neurotoxicity is rarely reported in advanced renal failure. We described a 63-year-old diabetes woman with advanced renal failure (estimated creatinine clearance of 8 mL/min) not yet dialysis received the standard dose...

Seventy infants with suspected bacterial infection in the first 48 hours of life were treated either with piperacillin and flucloxacillin or with penicillin and gentamicin. Infection was confirmed and successfully eradicated in 6 of the 35 infants receiving piperacillin and flucloxacillin. Four infants treated with penicillin and gentamicin had confirmed infection and one deteriorated initially...

BACKGROUND Piperacillin levels after standard dosing have been shown frequently to be subtherapeutic, especially when renal clearance was augmented. Here, we aimed to determine if piperacillin was in its therapeutic range in a typically heterogeneous intensive care unit patient group, and also to describe target attainment dependent on daily dosage, creatinine clearance, and renal replacement t...

Nosocomial pneumonia and acute peritonitis may be caused by a wide array of pathogens, and combination therapy is often recommended. We have previously shown that imipenem-cilastatin monotherapy was as efficacious as the combination of imipenem-cilastatin plus netilmicin in these two settings. The efficacy of imipenem-cilastatin is now compared to that of piperacillin-tazobactam as monotherapy ...

Abstract Background Excess of acute kidney injury (AKI) secondary to the association vancomycin plus piperacillin is debated. Objectives To detect a signal for an increased risk AKI with and combination compared other vancomycin-based regimens. Methods Using VigiBase, WHO global database individual case safety reports (ICSR) from 1997 2019, we conducted disproportionality analysis comparing rep...

Piperacillin-tazobactam is one of the most common causes of drug-induced immune hemolytic anemia (DIIHA) and is frequently utilized, especially in patients with cystic fibrosis (CF). Here, we report a case of life-threatening piperacillin-tazobactam-associated DIIHA in a 30-year-old woman with CF and propose management recommendations for piperacillin-tazobactam-associated DIIHA in CF patients.

BACKGROUND Standard therapy for suspected infections in patients with profound neutropenia is the combination of a beta-lactam antibiotic plus an aminoglycoside. Cefepime's broad-spectrum activity makes it an option for initial empirical therapy in neutropenic patients. The aim of this study is to evaluate the efficacy and safety of cefepime plus amikacin compared with piperacillin-tazobactam p...